Stock Financial Ratios

XLRN / Acceleron Pharma Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,391.02
Enterprise Value ($M)1,366.16
Book Value ($M)225.60
Book Value / Share6.03
Price / Book3.88
NCAV ($M)231.50
NCAV / Share6.18
Price / NCAV4.17
Income Statement (mra) ($M)
Net Income-57.01
Balance Sheet (mrq) ($M)
Cash & Equivalents238.96
Cash / Share6.38
Quick Ratio9.09
Current Ratio9.09
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.25
Return on Assets (ROA)-0.23
Return on Equity (ROE)-0.25
Identifiers and Descriptors
Central Index Key (CIK)1280600
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)45.24
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Retained Earnings Per Share-11.89
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Property Plant And Equipment Per Share0.19
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Liabilities And Stock Equity Per Share10.19
Assets Other Non Current Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Cash And Equivalents Per Share6.38
Accumulated Depreciation And Depletion Per Share0.00
Goodwill Per Share0.00
Liabilities Per Share0.61
Property Plant And Equipment Net Per Share0.19
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Inventory Raw Materials Per Share0.00
Equity Per Share9.58
Assets Current Per Share9.18
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Assets Per Share10.19
Inventory Per Share0.00
Additional Paid In Capital Per Share21.48
Cash Per Share6.38
Liabilities Current Per Share0.42

Related News Stories

Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195

2017-11-16 accesswire
LONDON, UK / ACCESSWIRE / November 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Loxo Oncology, Inc. (NASDAQ: LOXO), following which we have published a free report that can be viewed by signing up at The Company announced on November 14, 2017, that it has entered into a license, development, and commercialization agreement with Bayer Consumer Care AG wherein both the Companies will develop and commercialize Larotrectinib and LOXO-195 for the treatment of patients with TRK fusion cancers. (30-0)

Acceleron Pharma's (XLRN) CEO Habib Dable on Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Good day, ladies and gentlemen, and welcome to the Acceleron Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. As a reminder, this conference is being recorded. (2-0)

Options Traders Expect Huge Moves in Acceleron Pharma (XLRN) Stock

2017-10-18 zacks
Investors in Acceleron Pharma Inc. (XLRN - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 20th 2017 $50.00 Put had some of the highest implied volatility of all equity options today. (7-0)

Acceleron's Unique Pipeline Looks Undervalued

2017-10-12 seekingalpha
It has been over two years since I wrote Acceleron Pharma (XLRN) Has Two Potential Blockbusters, so an update is in order. Back then, on July 22, 2015, Acceleron closed at $32.18. It has been very volatile in the meantime, hitting $50.49 on December 29, 2015, but also $21.99 on October 13, 2015. That is part of the thrill (or opportunity, or danger) of investing in clinical-state biotechnology companies. (56-0)

BRIEF-Acceleron announces pricing of public offering of common stock

2017-09-21 reuters
* Acceleron Pharma - Announced underwritten public offering of 5.4 million shares of common stock at a price to public of $37 per share Source text for Eikon: Further company coverage: (2-1)

CUSIP: 00434H108